search
Back to results

Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis

Primary Purpose

Osteoarthritis

Status
Unknown status
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Autologous bone marrow stem cells
Sponsored by
International Stemcell Services Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, stem cell implantation, bone marrow, autologous

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Must be able to give voluntary written (patients may not be able to write) consent.
  2. Must be able to understand study information provided to him.
  3. Age 30 to 70, inclusive
  4. OA Kellgren and Lawrence classification 3 & 4
  5. No ligamentous laxity i.e. stable
  6. Ability to understand and willingness to sign consent form
  7. The participant is able to comply with and understand the required visit schedule and all required tests and procedures.

Exclusion Criteria:

  1. Serious pre-existing medical conditions like Diabetes Mellitus, Chronic Renal Failure, Rheumatoid Arthritis, Collagen vascular diseases and Autoimmune diseases
  2. Pregnant or lactating woman
  3. Inflammatory arthritis
  4. Oral steroid, methotrexate (immune suppressants)
  5. History of drug or alcohol abuse or chronic smoking
  6. Poor patient compliance
  7. Infectious disease test positive for HIV 1&2, HbsAg, HCV and VDRL.

Sites / Locations

  • St. Theresa's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Autologous bone marrow stem cells

Arm Description

Outcomes

Primary Outcome Measures

Pain as measured by the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Secondary Outcome Measures

Changes in the MRI knee with cartilage mapping and clinical improvement

Full Information

First Posted
June 25, 2010
Last Updated
June 8, 2011
Sponsor
International Stemcell Services Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01152125
Brief Title
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis
Official Title
Use of Autologous Bone Marrow Stem Cell Transplantation for Therapeutic Chondrogenesis in Moderate to Severe Osteoarthritis - ABM & LAM ST-OA Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Unknown status
Study Start Date
January 2010 (undefined)
Primary Completion Date
August 2011 (Anticipated)
Study Completion Date
January 2012 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
International Stemcell Services Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Osteoarthritis is a leading cause of chronic disability in elderly and the risk of disability attributed to osteoarthritis is as great as or greater than due to any other medical condition in that age group. Several cross sectional studies have demonstrated an age related increase in the prevalence of osteoarthritis of knee(5). Results of survey are similar with most surgeons reporting 50+ years age group being commonest at initial presentation and that the incidence increases with advancing age. Interestingly some surgeons have noticed earlier occurrence of osteoarthritis in 40+ years age group and one has to be careful to screen for secondary causes in this younger age group patients. While pain relief is the primary treatment goal of osteoarthritis medications, localized inflammation may also be relieved by using certain drugs. Managing osteoarthritis pain can involve medications, natural remedies, exercise, weight loss, joint protection, mobility aids, assisted devices and more. Stem cell therapy, using cells extracted from the same patient or suitable alternative human sources, targets diseases which are either incurable or with no complete or effective treatment available in the traditional healthcare system. Since this therapy is based on the concept of regenerating damaged cells in the injured or disease-affected areas of the body, it is called regenerative medicine Autologous stem cells provide an attractive option for osteoarthritis patients and their clinicians. In our present study we want to evaluate the safety and efficacy of autologous bone marrow derived stem cells in treatment of Osteoarthritis for therapeutic chondrogenesis through delivery of stem cells into the knee joint space in ten Indian patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Osteoarthritis, stem cell implantation, bone marrow, autologous

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Autologous bone marrow stem cells
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Autologous bone marrow stem cells
Intervention Description
Stem cells isolated from the patient's own bone marrow.
Primary Outcome Measure Information:
Title
Pain as measured by the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
Time Frame
Baseline, 3 months, 6 months, 1 year
Title
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Changes in the MRI knee with cartilage mapping and clinical improvement
Time Frame
Baseline, 6 months, 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be able to give voluntary written (patients may not be able to write) consent. Must be able to understand study information provided to him. Age 30 to 70, inclusive OA Kellgren and Lawrence classification 3 & 4 No ligamentous laxity i.e. stable Ability to understand and willingness to sign consent form The participant is able to comply with and understand the required visit schedule and all required tests and procedures. Exclusion Criteria: Serious pre-existing medical conditions like Diabetes Mellitus, Chronic Renal Failure, Rheumatoid Arthritis, Collagen vascular diseases and Autoimmune diseases Pregnant or lactating woman Inflammatory arthritis Oral steroid, methotrexate (immune suppressants) History of drug or alcohol abuse or chronic smoking Poor patient compliance Infectious disease test positive for HIV 1&2, HbsAg, HCV and VDRL.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rudraprasad, M.S
Organizational Affiliation
St. Theresa's Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alphy Zachson, M.B.B.S
Organizational Affiliation
International Stemcell Services Limited
Official's Role
Study Director
Facility Information:
Facility Name
St. Theresa's Hospital
City
Bengaluru
State/Province
Karnataka
ZIP/Postal Code
560010
Country
India

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis

We'll reach out to this number within 24 hrs